The invention relates to pyrido[3,2-e]pyrazines, to processes for
preparing them, to pharmaceutical compositions which comprise these
compounds and to the pharmaceutical use of these compounds, which are
inhibitors of phosphodiesterase 10, as active compounds for treating
central nervous system disorders, obesity, and metabolic disorders.